Please enable JavaScript to continue using this application.

Compare $CLCS vs $MGX | Chartloom

Compare

$CLCS vs $MGX

Cell Source Inc · Metagenomi Therapeutics Inc

CLCS

Cell Source Inc

MGX

Metagenomi Therapeutics Inc

Compare $CLCS vs $MGX

Comparing Cell Source Inc and Metagenomi Therapeutics Inc

CLCSCell Source Inc

MGXMetagenomi Therapeutics Inc

CLCSCell Source Inc

Market cap

$37M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-9.1%

52W performance

76.1%

FCF yield

-8.4%

MGXMetagenomi Therapeutics Inc

Market cap

$38M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.83x

Rev growth (TTM)

-50.7%

YTD performance

-40.1%

52W performance

-68.7%

FCF yield

-227.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLCS

MGX

Detailed metrics comparison

CLCS

Cell Source Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

CLCS$37M

MGX$38M

Enterprise Value

CLCS$48M

MGX$-1M

Price

CLCS$0.55

MGX$1.00

P/E Ratio

CLCSN/A

MGXN/A

P/S Ratio

CLCS0.00x

MGX2.72x

EV/Sales

CLCS0.00x

MGX-0.10x

EV/EBITDA

CLCS0.00x

MGX0.00x

P/B Ratio

CLCSN/A

MGX0.34x

P/FCF Ratio

CLCSN/A

MGXN/A

EV/FCF

CLCS-15.29x

MGX0.02x

PEG Ratio

CLCSN/A

MGXN/A

Forward P/E (NTM)

CLCSN/A

MGXN/A

Forward P/S (NTM)

CLCSN/A

MGX3.83x

Revenue (TTM)

CLCS$0

MGX$14M

Revenue Growth (YoY)

CLCSN/A

MGX-50.7%

Forward Rev Growth

CLCS0.0%

MGX30.0%

Gross Margin (TTM)

CLCS0.0%

MGX0.0%

Operating Margin (TTM)

CLCS0.0%

MGX0.0%

EBITDA Margin (TTM)

CLCS0.0%

MGX-491.3%

Net Margin (TTM)

CLCS0.0%

MGX-477.5%

FCF Margin (TTM)

CLCSN/A

MGX-620.9%

Net Income (TTM)

CLCS$-6M

MGX$-66M

FCF (TTM)

CLCS$-3M

MGX$-86M

EPS (TTM)

CLCS-$0.14

MGX$0.00

ROE (TTM)

CLCS-184198.9%

MGX-5123.0%

ROA (TTM)

CLCS-148238.0%

MGX-3662.0%

ROIC (TTM)

CLCS0.0%

MGX-5123.0%

Cash

CLCS$1K

MGX$39M

Debt

CLCS$11M

MGX$0

Net Cash/Debt

CLCS$-10M

MGX$39M

Current Ratio (TTM)

CLCS0.01x

MGX4.50x

Quick Ratio (TTM)

CLCS0.00x

MGX4.37x

Debt/Equity (TTM)

CLCS0.00x

MGX0.00x

Debt/Assets (TTM)

CLCS0.0%

MGX0.0%

Interest Coverage (TTM)

CLCSN/A

MGXN/A

Net Debt/EBITDA (TTM)

CLCS0.00x

MGX0.00x

Beta

CLCS23.26

MGX0.68

52W Performance

CLCS76.1%

MGX-68.7%

YTD Performance

CLCS-9.1%

MGX-40.1%

% from 52W High

CLCS-75.8%

MGX-74.7%

% from 52W Low

CLCS199.8%

MGX4.2%

Asset Turnover (TTM)

CLCS0.00x

MGX0.10x

FCF Yield (TTM)

CLCS-8.4%

MGX-227.9%

Earnings Yield (TTM)

CLCS-16.5%

MGX-175.2%

Dividend Yield (TTM)

CLCSN/A

MGXN/A

Rule of 40

CLCS0.0

MGX-671.6

EV/GP/RG

CLCSN/A

MGXN/A

Ticker research

View CLCS research View MGX research

Metric	CLCS Cell Source Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$37M	$38M
Enterprise Value	$48M	$-1M
Price	$0.55	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.72x
EV/Sales	0.00x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	N/A	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.29x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$0	$14M
Revenue Growth (YoY)	N/A	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-491.3%
Net Margin (TTM)	0.0%	-477.5%
FCF Margin (TTM)	N/A	-620.9%
Net Income (TTM)	$-6M	$-66M
FCF (TTM)	$-3M	$-86M
EPS (TTM)	-$0.14	$0.00
ROE (TTM)	-184198.9%	-5123.0%
ROA (TTM)	-148238.0%	-3662.0%
ROIC (TTM)	0.0%	-5123.0%
Financial Health
Cash	$1K	$39M
Debt	$11M	$0
Net Cash/Debt	$-10M	$39M
Current Ratio (TTM)	0.01x	4.50x
Quick Ratio (TTM)	0.00x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	23.26	0.68
52W Performance	76.1%	-68.7%
YTD Performance	-9.1%	-40.1%
% from 52W High	-75.8%	-74.7%
% from 52W Low	199.8%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.10x
FCF Yield (TTM)	-8.4%	-227.9%
Earnings Yield (TTM)	-16.5%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View CLCS research	View MGX research

Valuation

P/S Ratio

CLCS

0.00x

MGX

2.72x

EV/FCF

CLCS

-15.29x

MGX

0.02x

Growth & revenue

Revenue Growth TTM

MGX

-50.7%

Forward Revenue Growth

MGX

30.0%

CLCS

0.0%

Profitability & performance

Gross Margin

CLCS

0.0%

MGX

0.0%

ROE

MGX

-5123.0%

CLCS

-184198.9%

FCF Yield %

CLCS

-8.4%

MGX

-227.9%

52-Week Performance

CLCS

76.1%

MGX

-68.7%

Detailed metrics comparison

CLCS

Cell Source Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

CLCS$37M

MGX$38M

Enterprise Value

CLCS$48M

MGX$-1M

Price

CLCS$0.55

MGX$1.00

P/E Ratio

CLCSN/A

MGXN/A

P/S Ratio

CLCS0.00x

MGX2.72x

EV/Sales

CLCS0.00x

MGX-0.10x

EV/EBITDA

CLCS0.00x

MGX0.00x

P/B Ratio

CLCSN/A

MGX0.34x

P/FCF Ratio

CLCSN/A

MGXN/A

EV/FCF

CLCS-15.29x

MGX0.02x

PEG Ratio

CLCSN/A

MGXN/A

Forward P/E (NTM)

CLCSN/A

MGXN/A

Forward P/S (NTM)

CLCSN/A

MGX3.83x

Revenue (TTM)

CLCS$0

MGX$14M

Revenue Growth (YoY)

CLCSN/A

MGX-50.7%

Forward Rev Growth

CLCS0.0%

MGX30.0%

Gross Margin (TTM)

CLCS0.0%

MGX0.0%

Operating Margin (TTM)

CLCS0.0%

MGX0.0%

EBITDA Margin (TTM)

CLCS0.0%

MGX-491.3%

Net Margin (TTM)

CLCS0.0%

MGX-477.5%

FCF Margin (TTM)

CLCSN/A

MGX-620.9%

Net Income (TTM)

CLCS$-6M

MGX$-66M

FCF (TTM)

CLCS$-3M

MGX$-86M

EPS (TTM)

CLCS-$0.14

MGX$0.00

ROE (TTM)

CLCS-184198.9%

MGX-5123.0%

ROA (TTM)

CLCS-148238.0%

MGX-3662.0%

ROIC (TTM)

CLCS0.0%

MGX-5123.0%

Cash

CLCS$1K

MGX$39M

Debt

CLCS$11M

MGX$0

Net Cash/Debt

CLCS$-10M

MGX$39M

Current Ratio (TTM)

CLCS0.01x

MGX4.50x

Quick Ratio (TTM)

CLCS0.00x

MGX4.37x

Debt/Equity (TTM)

CLCS0.00x

MGX0.00x

Debt/Assets (TTM)

CLCS0.0%

MGX0.0%

Interest Coverage (TTM)

CLCSN/A

MGXN/A

Net Debt/EBITDA (TTM)

CLCS0.00x

MGX0.00x

Beta

CLCS23.26

MGX0.68

52W Performance

CLCS76.1%

MGX-68.7%

YTD Performance

CLCS-9.1%

MGX-40.1%

% from 52W High

CLCS-75.8%

MGX-74.7%

% from 52W Low

CLCS199.8%

MGX4.2%

Asset Turnover (TTM)

CLCS0.00x

MGX0.10x

FCF Yield (TTM)

CLCS-8.4%

MGX-227.9%

Earnings Yield (TTM)

CLCS-16.5%

MGX-175.2%

Dividend Yield (TTM)

CLCSN/A

MGXN/A

Rule of 40

CLCS0.0

MGX-671.6

EV/GP/RG

CLCSN/A

MGXN/A

Ticker research

View CLCS research View MGX research

Metric	CLCS Cell Source Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$37M	$38M
Enterprise Value	$48M	$-1M
Price	$0.55	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.72x
EV/Sales	0.00x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	N/A	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.29x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$0	$14M
Revenue Growth (YoY)	N/A	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-491.3%
Net Margin (TTM)	0.0%	-477.5%
FCF Margin (TTM)	N/A	-620.9%
Net Income (TTM)	$-6M	$-66M
FCF (TTM)	$-3M	$-86M
EPS (TTM)	-$0.14	$0.00
ROE (TTM)	-184198.9%	-5123.0%
ROA (TTM)	-148238.0%	-3662.0%
ROIC (TTM)	0.0%	-5123.0%
Financial Health
Cash	$1K	$39M
Debt	$11M	$0
Net Cash/Debt	$-10M	$39M
Current Ratio (TTM)	0.01x	4.50x
Quick Ratio (TTM)	0.00x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	23.26	0.68
52W Performance	76.1%	-68.7%
YTD Performance	-9.1%	-40.1%
% from 52W High	-75.8%	-74.7%
% from 52W Low	199.8%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.10x
FCF Yield (TTM)	-8.4%	-227.9%
Earnings Yield (TTM)	-16.5%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View CLCS research	View MGX research